Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
Source: View publication →
In two Phase 3 trials, the oral BTK inhibitor remibrutinib demonstrated superior efficacy over teriflunomide in reducing annualized relapse rates and MRI lesion activity in patients with relapsing multiple sclerosis, while maintaining a favorable liver safety profile.
Key Findings
Study Design
Study Limitations
Clinical Significance
Remibrutinib provides a highly effective oral treatment option for relapsing multiple sclerosis that circumvents the need for chronic broad B-cell depletion. The trial's demonstration of robust efficacy coupled with the absence of significant hepatotoxicity mitigates major safety concerns that have plagued other BTK inhibitors in development, positioning remibrutinib as a vital new addition to the MS therapeutic armamentarium.
Historical Context
The treatment of relapsing MS has advanced from early injectables to highly effective anti-CD20 monoclonal antibodies, which achieve profound disease control but cause chronic B-cell depletion, increasing infection risks and blunting vaccine responses. BTK inhibitors emerged as an attractive oral alternative capable of modulating both peripheral B-cells and CNS microglia without causing cell lysis. However, the class has been shadowed by setbacks, including liver toxicity and trial failures (e.g., evobrutinib). The REMODEL trials provide pivotal validation that a highly selective BTK inhibitor can achieve both superior efficacy and a favorable safety profile.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of Bruton's tyrosine kinase (BTK) inhibitors, such as remibrutinib, differ fundamentally from anti-CD20 monoclonal antibodies (like ocrelizumab) in the treatment of multiple sclerosis?
Key Response
BTK inhibitors modulate B-cell function and maturation without causing B-cell depletion, unlike anti-CD20 therapies which cause cell lysis. Additionally, BTK inhibitors are small molecules that can cross the blood-brain barrier to modulate microglia, a key driver of smoldering neuroinflammation in MS.
Given the history of hepatotoxicity leading to clinical holds for other BTK inhibitors in MS trials, how should the liver safety profile of remibrutinib influence the frequency and duration of liver function monitoring if approved for clinical use, compared to the comparator teriflunomide?
Key Response
While remibrutinib demonstrated a favorable liver safety profile in the REMODEL trials, the BTK inhibitor class carries a known risk of transaminitis. Residents must weigh class effects against specific trial data when establishing monitoring protocols, contrasting this with teriflunomide's well-established black-box warning requiring monthly LFTs for six months.
BTK inhibitors are theoretically well-positioned to address Progression Independent of Relapse Activity (PIRA) due to their CNS penetrance. Based on the REMODEL trial design, how effectively do the primary endpoints capture the impact of remibrutinib on smoldering disease versus acute inflammatory relapses?
Key Response
The primary endpoints of REMODEL-1 and 2 (ARR and acute MRI lesions) heavily weight acute, focal inflammation. Fellows must critically evaluate whether secondary endpoints like brain volume loss, 6-month confirmed disability worsening, and advanced MRI metrics were adequately powered to prove the theoretical microglial and PIRA benefits of BTK inhibition.
If remibrutinib gains regulatory approval, where does an oral, non-depleting, CNS-penetrant B-cell modulator fit within our current treatment algorithm, particularly for patients hesitant about infusions or concerned about vaccine efficacy?
Key Response
Attendings must contextualize new drugs in shared decision-making. Remibrutinib offers B-cell pathway targeting without absolute depletion, potentially allowing for better vaccine responses and lower infection risks compared to anti-CD20s, making it an attractive first-line high-efficacy oral option over older orals.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The REMODEL trials utilized teriflunomide as the active comparator. From a methodological standpoint, how does the selection of a lower-efficacy first-generation oral therapy impact the generalizability of the superiority findings, and what statistical methods are required to estimate remibrutinib's efficacy against current high-efficacy standards?
Key Response
Using teriflunomide maximizes the likelihood of proving superiority but limits real-world comparative effectiveness insights. Researchers would need to utilize Network Meta-Analyses (NMA) or Matching-Adjusted Indirect Comparisons (MAIC) to estimate relative efficacy against contemporary agents like S1P modulators or anti-CD20s.
As a reviewer evaluating the claim of a 'favorable liver safety profile,' what specific details regarding the adjudication of liver injury events and handling of missing data due to adverse events would you scrutinize to ensure the findings are robust against class-effect bias?
Key Response
Because liver toxicity is the major vulnerability of MS BTK inhibitors, a strict editorial review must evaluate the predefined criteria for Drug-Induced Liver Injury (e.g., Hy's Law), patient discontinuation rates due to asymptomatic transaminase elevations, and whether follow-up was sufficient to capture delayed hepatotoxicity.
Current ECTRIMS and AAN guidelines do not yet incorporate BTK inhibitors. Given the Class I evidence from the REMODEL trials, should remibrutinib be strongly recommended as a first-line treatment for treatment-naive active RMS, or should its use be conditional based on long-term safety data?
Key Response
Two well-designed Phase 3 RCTs provide high-level evidence for remibrutinib's superiority over teriflunomide. Guidelines committees must establish if this warrants a strong first-line recommendation, balancing its novel mechanism and oral convenience against the lack of decade-long safety data currently available for established high-efficacy therapies.
Clinical Landscape
Noteworthy Related Trials
TEMSO Trial
Tested
Teriflunomide 7mg or 14mg daily
Population
Patients with relapsing multiple sclerosis
Comparator
Placebo
Endpoint
Annualized relapse rate
Evobrutinib Phase 2 Trial
Tested
Evobrutinib 75mg once or twice daily
Population
Patients with relapsing multiple sclerosis
Comparator
Placebo
Endpoint
Total number of gadolinium-enhancing T1 lesions
ASCLEPIOS I and II
Tested
Ofatumumab 20mg subcutaneously monthly
Population
Patients with relapsing multiple sclerosis
Comparator
Teriflunomide 14mg daily
Endpoint
Annualized relapse rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis